- Home
- XBIT vs MDWD Comparison
XBIT vs MDWD Comparison
Compare XBIT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- MDWD
- Stock Information
- Founded
- XBIT 2005
- MDWD 2000
- Country
- XBIT United States
- MDWD Israel
- Employees
- XBIT N/A
- MDWD N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- XBIT Health Care
- MDWD Health Care
- Exchange
- XBIT Nasdaq
- MDWD Nasdaq
- Market Cap
- XBIT 89.6M
- MDWD 230.6M
- IPO Year
- XBIT 2015
- MDWD 2014
- Fundamental
- Price
- XBIT $3.22
- MDWD $19.12
- Analyst Decision
- XBIT
- MDWD Strong Buy
- Analyst Count
- XBIT 0
- MDWD 2
- Target Price
- XBIT N/A
- MDWD $35.00
- AVG Volume (30 Days)
- XBIT 190.4K
- MDWD 48.5K
- Earning Date
- XBIT 08-11-2025
- MDWD 08-13-2025
- Dividend Yield
- XBIT N/A
- MDWD N/A
- EPS Growth
- XBIT N/A
- MDWD N/A
- EPS
- XBIT N/A
- MDWD N/A
- Revenue
- XBIT N/A
- MDWD $19,213,000.00
- Revenue This Year
- XBIT N/A
- MDWD $20.80
- Revenue Next Year
- XBIT N/A
- MDWD $26.92
- P/E Ratio
- XBIT N/A
- MDWD N/A
- Revenue Growth
- XBIT N/A
- MDWD N/A
- 52 Week Low
- XBIT $2.50
- MDWD $14.14
- 52 Week High
- XBIT $8.32
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- XBIT 65.65
- MDWD 40.24
- Support Level
- XBIT $2.58
- MDWD $19.11
- Resistance Level
- XBIT $2.78
- MDWD $19.87
- Average True Range (ATR)
- XBIT 0.18
- MDWD 0.63
- MACD
- XBIT 0.07
- MDWD -0.17
- Stochastic Oscillator
- XBIT 87.85
- MDWD 25.31
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.